Background: Lipoprotein Lipase (LPL) is a key enzyme in lipid metabolism, especially for plasma triglycerides (TG). Genetic variants have been associated to lipid levels in healthy individuals, cardiovascular disease, obesity and diabetes. Our aim was to evaluate the influence of three polymorphisms: Hind III, Pvu II and S447X in plasma TG levels in Human Immunodeficiency Virus-1 (HIV-1) infected children under Highly Active Antiretroviral Therapy (HAART).
Methods: 52 children diagnosed with HIV-1 between 2005 and 2009, were retrospectively selected with at least one plasma TG level assessment. TG levels were examined before and after one-year of HAART. Hypertriglyceridemia was defined as TG>150 mg/dL. Hind III (H+/H-), Pvu II (P+/P-) and S447X (S/X) were determined by PCR-RFLP. Wilcoxon sum rank test was used to compare median plasma TG among groups. Also, allelic frequencies were estimated for these variants in Argentinean population.
Results: Allelic frequencies for HIV-1 infected children were: H-, 0.21; P-, 0.53 and X, 0.05 with no significant differences to controls. After one-year of HAART, median TG levels were significantly lower in P-/P- (98.5 mg/dL) when compared to P+/P+ (180 mg/dL) (p=0.039). The presence of P- allele was associated with an 11-fold lower risk of hypertriglyceridemia. Hind III and S447X were not associated with TG at the selected time points.
Conclusions: Our findings suggest a protective effect of LPL polymorphisms against hypertriglyceridemia in children after one-year HAART. These results could endorse a prompt nutritional or pharmacological intervention in patients lacking the P- allele.
(C) 2014 by Lippincott Williams & Wilkins, Inc.